FI120497B - Interleukin-15-antagonister - Google Patents

Interleukin-15-antagonister Download PDF

Info

Publication number
FI120497B
FI120497B FI973361A FI973361A FI120497B FI 120497 B FI120497 B FI 120497B FI 973361 A FI973361 A FI 973361A FI 973361 A FI973361 A FI 973361A FI 120497 B FI120497 B FI 120497B
Authority
FI
Finland
Prior art keywords
seq
peg
mutein
sequence
cells
Prior art date
Application number
FI973361A
Other languages
English (en)
Finnish (fi)
Other versions
FI973361A (sv
FI973361A0 (sv
Inventor
Kenneth H Grabstein
Dean K Pettit
Raymond J Paxton
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23550114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI120497(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of FI973361A0 publication Critical patent/FI973361A0/sv
Publication of FI973361A publication Critical patent/FI973361A/sv
Application granted granted Critical
Publication of FI120497B publication Critical patent/FI120497B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)

Claims (13)

1. Interleukin-15- (IL-15) aktivitetsantagonist, som är nativt IL-15:s mutein, som binds vid en IL-15-α- 5 underenhet av ett IL-15-receptorkomplex och omfattar minst en tillsats, substitution eller deletion, a) i aminosyran Asp56 av sekvens nr 1 eller sekvens nr 2 eller b) i aminosyran Gin156 av sekvens nr 1 eller sek- 10 vens nr 2, som hindrar IL-15 frän att överföra en signal via β- eller γ-underenheten av IL-15 receptorkomplexet.
2. Antagonist enligt patentkrav 1, som är IL-15:s mutein, väri ätminstone en av aminosyraresterna Asp56 el- 15 ler Gin156 antingen har deleterats eller substituerats med nagon annan naturligt förekommande aminosyrarest.
3. Antagonist enligt patentkrav 2, vari antingen Asp56 eller GlnliS eller bäda har vardera substituerats med serin eller cystein.
4. Antagonist enligt patentkrav 3, vari Asp56 har substituerats med serin eller cystein.
5. Antagonist enligt patentkrav 3, vari Gin156 har substituerats med serin eller cystein.
6. Isolerad nukleinsyrasekvens, som kodar för ett
25 IL-15-mutein enligt patentkrav 1.
7. Isolerad nukleinsyra enligt patentkrav 6, när i IL-15-muteinet atminstone en av aminosyraresterna Asp55 eller Gin156 antingen har deleterats eller substituerats med nagon annan naturligt förekommande aminosyrarest.
8. Isolerad nukleinsyra enligt patentkrav 7, när antingen Asp56 eller Gin156 eller bäda har vardera substituerats med serin eller cystein.
9. Isolerad nukleinsyra enligt patentkrav 7, när Asp56 har substituerats med serin eller cystein.
10. Isolerad nukleinsyra enligt patentkrav 7, när Gin156 har substituerats med serin eller cystein.
11. Rekombinant-DNA-vektor, som omfattar en nukle-insyra enligt patentkrav 6.
12. Värdcell, som har transformerats eller trans-fekterats med en vektor enligt patentkrav 11. 5
13. Förfarande för att producera ett IL--15-mutein enligt patentkrav 1, vilket förfarande omfattar odling av en värdcell enligt patentkrav 12 under odlingsförhällan-den, som leder till exprimering av dylikt IL-15-mutein.
FI973361A 1995-02-22 1997-08-15 Interleukin-15-antagonister FI120497B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39231795 1995-02-22
US08/392,317 US5795966A (en) 1995-02-22 1995-02-22 Antagonists of interleukin-15
US9602520 1996-02-21
PCT/US1996/002520 WO1996026274A1 (en) 1995-02-22 1996-02-21 Antagonists of interleukin-15

Publications (3)

Publication Number Publication Date
FI973361A0 FI973361A0 (sv) 1997-08-15
FI973361A FI973361A (sv) 1997-10-15
FI120497B true FI120497B (sv) 2009-11-13

Family

ID=23550114

Family Applications (2)

Application Number Title Priority Date Filing Date
FI973361A FI120497B (sv) 1995-02-22 1997-08-15 Interleukin-15-antagonister
FI20060080A FI121571B (sv) 1995-02-22 2006-01-27 Interleukin-15-antagonister

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20060080A FI121571B (sv) 1995-02-22 2006-01-27 Interleukin-15-antagonister

Country Status (16)

Country Link
US (5) US5795966A (sv)
EP (2) EP0811065B2 (sv)
JP (2) JPH11500908A (sv)
KR (1) KR19980702238A (sv)
AT (1) ATE339505T1 (sv)
AU (1) AU708549B2 (sv)
CA (2) CA2637795C (sv)
DE (1) DE69636538T3 (sv)
DK (1) DK0811065T4 (sv)
ES (1) ES2271951T5 (sv)
FI (2) FI120497B (sv)
MX (1) MX9706294A (sv)
NO (2) NO321990B1 (sv)
NZ (1) NZ303843A (sv)
PT (1) PT811065E (sv)
WO (1) WO1996026274A1 (sv)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US7192935B1 (en) 1993-03-08 2007-03-20 Amgen Inc. Polynucleotides encoding epithelium-derived T-cell factor and uses thereof
AU680909B2 (en) * 1994-04-06 1997-08-14 Immunex Corporation Interleukin-15
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
AUPN378095A0 (en) * 1995-06-23 1995-07-20 Bresagen Limited Haemopoietic growth factor antagonists and uses therefor
US6001973A (en) * 1996-04-26 1999-12-14 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
DK0927254T3 (da) * 1996-04-26 2005-10-03 Beth Israel Hospital Interleukin-15-antagonister
JP2001503253A (ja) * 1996-10-17 2001-03-13 イムノメディクス，インコーポレイテッド 非抗原性即素複合体およびインターナライジング受容体システムの融合タンパク
US5874566A (en) * 1996-10-25 1999-02-23 Hisamitsu Pharmaceutical Co. Inc. Il-15 triplex oligonucleotides
ATE295736T1 (de) * 1997-02-21 2005-06-15 Vlaams Interuniv Inst Biotech Verwendung von interleukin-15
US20030013668A1 (en) * 1998-07-07 2003-01-16 Dange Veerapanane Ph.D Antisense oligonucleotides targeted to il-15
GB9814892D0 (en) * 1998-07-10 1998-09-09 Kennedy Rheumatology Inst Treatment of celiac disease
US5985663A (en) * 1998-11-25 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of interleukin-15 expression
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
EP1881070B1 (en) * 1999-03-09 2012-10-03 Zymogenetics, Inc. Human cytokine as ligand of the zalpha receptor and uses thereof
AU6689700A (en) * 1999-07-06 2001-01-22 Silvia Bulfone-Paus Method of treating psoriasis with il-15 antagonist
EP1226173A1 (en) * 1999-10-07 2002-07-31 Maxygen Aps Single-chain antagonist polypeptides
CN1441675A (zh) * 2000-05-12 2003-09-10 贝斯以色列护理医疗中心有限公司 免疫抑制组合物及方法
WO2002022805A2 (en) 2000-09-14 2002-03-21 Beth Israel Deaconess Medical Center, Inc. Modulation of il-2- and il-15-mediated t cell responses
WO2003007685A2 (en) 2001-07-17 2003-01-30 University Of Florida Detecting and treating reproductive tract disorders
JP4359503B2 (ja) * 2001-08-23 2009-11-04 ゲンマブ エー／エス インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体
US7329405B2 (en) * 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
CN101483523A (zh) * 2002-04-15 2009-07-15 株式会社Ntt都科摩 利用双线性映射的签名方案
CU23093A1 (es) * 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech Composición vacunal que comprende interleucina-15 (il-15)
JP4892335B2 (ja) * 2003-02-26 2012-03-07 ゲンマブ エー／エス インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体
EP1656410B1 (en) * 2003-07-22 2010-03-10 Nektar Therapeutics Method for preparing functionalized polymers from polymer alcohols
ES2367027T3 (es) * 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
WO2006020849A2 (en) * 2004-08-11 2006-02-23 Beth Israel Deaconess Medical Center, Inc. Mutant interleukin-15 polypeptides
CU23472A1 (es) * 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
EP1807109A2 (en) * 2004-10-05 2007-07-18 Ochsner Clinic Foundation Enhancement of b cell proliferation by il-15
PL1899364T3 (pl) 2005-05-17 2020-08-24 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US8055951B2 (en) * 2007-04-10 2011-11-08 International Business Machines Corporation System, method and computer program product for evaluating a virtual machine
DK2769984T3 (en) 2007-05-11 2017-10-16 Altor Bioscience Corp Fusion molecules and IL-15 variants
CU23716A1 (es) * 2008-09-30 2011-10-05 Ct Ingenieria Genetica Biotech Péptido antagonista de la actividad de la interleucina-15
US20100145285A1 (en) * 2008-12-09 2010-06-10 Cook Critical Care, Incorporated Multi-lumen catheter configuration
EP2614151B1 (en) * 2010-09-08 2019-07-24 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
PT2918607T (pt) 2010-09-21 2018-01-11 Altor Bioscience Corp Moléculas de fusão de il-15 multiméricas solúveis e métodos de produção e utilização das mesmas
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
ES2778053T3 (es) 2011-01-18 2020-08-07 Bioniz Llc Composiciones para modular la actividad de la citocina gamma-c
CA2909576C (en) 2013-04-19 2023-07-18 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
EP3912637A1 (en) 2014-06-30 2021-11-24 Altor BioScience Corporation Il-15-based molecules and methods of use thereof
US10333696B2 (en) 2015-01-12 2019-06-25 X-Prime, Inc. Systems and methods for implementing an efficient, scalable homomorphic transformation of encrypted data with minimal data expansion and improved processing efficiency
CN108350032A (zh) 2015-10-09 2018-07-31 比奥尼斯有限责任公司 调节γC-细胞因子活性
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
WO2017120479A1 (en) * 2016-01-07 2017-07-13 The Schepens Eye Research Institute, Inc. Therapeutics for ocular immunoinflammatory diseases
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
US20180200366A1 (en) 2016-10-21 2018-07-19 Altor Bioscience Corporation Multimeric il-15-based molecules
US11267883B2 (en) * 2016-12-21 2022-03-08 Cephalon, Inc. Antibodies that specifically bind to human IL-15 and uses thereof
CU24546B1 (es) 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
CN111432836A (zh) 2017-09-05 2020-07-17 转矩医疗股份有限公司 治疗性蛋白质组合物及其制备和使用方法
CU24545B1 (es) 2017-12-29 2021-09-07 Ct Ingenieria Genetica Biotecnologia Péptido antagonista de la actividad de la interleucina-15
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
EP0276846A3 (en) 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
SG47099A1 (en) * 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5552303A (en) 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
US5591630A (en) * 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
US5696234A (en) 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
ES2304786T3 (es) † 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
EP0823941A4 (en) † 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES

Also Published As

Publication number Publication date
EP1770163A2 (en) 2007-04-04
KR19980702238A (ko) 1998-07-15
FI973361A (sv) 1997-10-15
US6013480A (en) 2000-01-11
DE69636538T2 (de) 2007-05-16
MX9706294A (es) 1997-10-31
JP2008133276A (ja) 2008-06-12
US5795966A (en) 1998-08-18
US6168783B1 (en) 2001-01-02
US6165466A (en) 2000-12-26
DE69636538D1 (de) 2006-10-26
EP0811065B2 (en) 2010-06-30
AU708549B2 (en) 1999-08-05
FI20060080A (sv) 2006-01-27
NO973705D0 (no) 1997-08-12
JPH11500908A (ja) 1999-01-26
WO1996026274A1 (en) 1996-08-29
FI121571B (sv) 2011-01-14
NZ303843A (en) 1999-04-29
FI973361A0 (sv) 1997-08-15
CA2637795A1 (en) 1996-08-29
EP1770163A3 (en) 2008-10-22
ES2271951T3 (es) 2007-04-16
DK0811065T3 (da) 2006-11-20
DE69636538T3 (de) 2010-10-28
EP0811065B1 (en) 2006-09-13
EP0811065A1 (en) 1997-12-10
ES2271951T5 (es) 2010-11-29
PT811065E (pt) 2007-01-31
NO973705L (no) 1997-10-22
CA2210491A1 (en) 1996-08-29
CA2210491C (en) 2008-11-18
CA2637795C (en) 2011-01-18
DK0811065T4 (da) 2010-08-23
AU5027596A (en) 1996-09-11
ATE339505T1 (de) 2006-10-15
NO321990B1 (no) 2006-07-31
US6177079B1 (en) 2001-01-23
NO20060194L (no) 1997-10-22

Similar Documents

Publication Publication Date Title
FI120497B (sv) Interleukin-15-antagonister
US7763434B2 (en) Antagonists of interleukin-15
KR100607609B1 (ko) Ｉｌ-2 선택성 작용제 및 길항제
KR102219124B1 (ko) 비글리코실화 Fc-함유 폴리펩티드
WO2015103928A1 (zh) Il-15异源二聚体蛋白及其用途
JP2000103799A (ja) 巨核球の成長と分化を刺激するｍｇｄｆの誘導体とその製造方法
US20100041586A1 (en) Method of improving efficacy of biological response-modifying proteins and the exemplary muteins
CN1382158A (zh) 多细胞因子－抗体复合物
CA2210724A1 (en) Human interleukin-1 receptor accessory protein
JP2001510687A (ja) 標的細胞の指向細胞溶解、細胞溶解を引き起こす薬剤および組成物、ならびにそのような薬剤を製造するために使用できる化合物
NZ234479A (en) Antagonists of gm-csf derived from the carboxyl terminus, antibodies, hybridomas and pharmaceutical compositions containing anti-idiotypic antibodies
WO2007075899A2 (en) Dual agonist compounds and uses thereof
WO1997010338A1 (en) Improved interleukin-6 receptor antagonist
WO1997010338A9 (en) Improved interleukin-6 receptor antagonist
CA2157785A1 (en) Pharmaceutical compositions comprising soluble interleukin-4 receptor and interleukin-4
CA2255906A1 (en) Human interleukin-1j and antagonists thereof
KR20220077590A (ko) Candida Utilis 유래 요산산화효소-알부민 복합체 및 이의 제조 방법

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120497

Country of ref document: FI

MM Patent lapsed